Results 1 to 10 of about 27,566 (187)
Nature Reviews Drug Discovery, 2003 Ezetimibe, a synthetic 2-azetidinone, is the first of a new class of compounds that selectively inhibits the absorption of cholesterol and related plant sterols in the intestine. The drug, and its glucuronyl metabolite, are thought to inhibit a putative cholesterol transporter of enterocytes, located within the brush-border membrane of the small ...
Malcolm J M, Darkes +2 more
exaly +12 more sources
Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events [PDF]
Annals of MedicineThe EWTOPIA 75 (Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older) study supports the reduction in the risk of atherosclerotic cardiovascular disease (ASCVD) events with ezetimibe without statin therapy
Alpo Vuorio +2 more
doaj +2 more sources
Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis [PDF]
Annals of MedicineBackground Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain ...
Areej S. Albawa’neh +6 more
doaj +2 more sources
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia [PDF]
Vascular Health and Risk Management, 2010 Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse21Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, AustraliaAbstract: High-dose potent statin therapy in ...
Ian Hamilton-Craig +3 more
doaj +3 more sources
Real-world evidence on the additional cancer risk reduction of ezetimibe: a 10-year nationwide retrospective cohort study emulating a target trial [PDF]
Journal of Cancer Research and Clinical OncologyBackground Lipid-lowering therapies, particularly statins, have been associated with a reduced risk of cancer. However, the potential additional protective effects of ezetimibe remain unclear in real-world settings. This study investigated whether statin/
Yohwan Lim +14 more
doaj +2 more sources
Bioscience Journal, 2023 Ezetimibe is an approved drug for lowering plasma LDL (low-density lipoprotein) level via inhibition of cholesterol absorption. Derivatives of ezetimibe reduce inflammatory response and oxidative stress.
Suhyeon Park, Ji-Soo Park, Sang-Kyu Park
doaj +1 more source
Разработка и регистрация лекарственных средств, 2023 Introduction. As a part of the registration of the drug product a bioequivalence study of the fixed-dose combination "Ezetimibe + rosuvastatin" (JSC "Sanofi-aventis group", Russia) compared with coadministered Ezetrol® (ezetimibe) and Crestor ...
A. L. Khokhlov +6 more
doaj +1 more source
PLoS ONE, 2023 Atherosclerosis and cardiovascular events can be prevented, or treated, using statin therapy, either alone or in combination with ezetimibe. Chronic inflammation, vascular proliferation, and the development of atherosclerosis are also influenced by 25 ...
Ewelina Woźniak +4 more
doaj +2 more sources
Ezetimibe and Cancer: Is There a Connection?
Frontiers in Pharmacology, 2022 The high level of serum cholesterol caused by the excessive absorption of cholesterol can lead to hypercholesteremia, thus promoting the occurrence and development of cancer.
Jia Gu +8 more
doaj +1 more source
Impact on urinary oxalate levels with use of ezetimibe
Endocrinology, Diabetes & Metabolism, 2021 Background Calcium oxalate stones are the most common cause of nephrolithiasis in the United States. Smaller studies of
Christopher L. Trautman +5 more
doaj +1 more source